Is ESTA a buy according to AI stock analysis?

ESTA AI stock analysis does not label Establishment Labs as an automatic buy because growth and valuation point in different directions. The business is growing revenue and expanding its market presence, but the stock trades near 11.6x TTM revenue with negative earnings, so a buyer needs confidence in sustained growth, US market share gains, and a credible path to profitability.

What is the ESTA AI stock forecast?

The ESTA AI stock forecast uses scenarios, not a guaranteed target. Around the $89.25 cutoff price, the bullish scenario is roughly $125 to $155, the base scenario is roughly $70 to $95, and the bearish scenario is roughly $40 to $55, depending on revenue growth, profitability timing, competitive dynamics, and valuation multiples.

What technical levels matter for ESTA?

The key ESTA technical levels are the $90 to $91 resistance zone (52-week high), the $78 to $82 near-support zone (50-day moving average area), and the $58 to $62 secondary support zone (200-day moving average area). A close below $78 would weaken near-term momentum.

Can AI predict ESTA stock price?

No, AI cannot reliably predict stock prices. AI can organize filings, market data, valuation math, technical levels, and risk scenarios, but ESTA can still move sharply after earnings, product announcements, regulatory events, macro shifts, or changes in elective procedure demand.

How should I use this ESTA AI trading strategy?

Use this ESTA AI trading strategy as a research checklist, not a personal instruction. Confirm live price, volume, moving averages, earnings timing, position size, stop level, and portfolio risk before making any trade.

What is the biggest risk in ESTA stock analysis?

The biggest risk in ESTA stock analysis is paying a premium revenue multiple for a company that is not yet profitable. Consumer sensitivity to elective aesthetic procedures, competitive entry by larger medtech firms, and the pace of US market adoption all matter because the current valuation leaves limited room for disappointment.

Establishment Labs Holdings Inc. research snapshot

ESTA AI Stock Analysis

ESTA AI stock analysis currently reads Establishment Labs Holdings Inc. as a high-growth medical aesthetics company with a leading breast implant franchise, improving revenue trajectory, and a path toward profitability that the market is already pricing optimistically. The analysis is not a certain price prediction. At the July 13, 2026 cutoff, the latest verified close used here was $89.25, market capitalization was about $2.63 billion, and the main question was whether Motiva Implants adoption, US market penetration, margin expansion, and operating leverage can justify a roughly 11.6x TTM revenue multiple for a company that is not yet profitable on a GAAP basis. This is informational research and not investment advice.

Current price

$89.25

Market cap

$2.63 billion

AI score

52 / 100

Rating

Improving business, speculative valuation

Trend status

Strong uptrend nearing 52-week highs

Data cutoff (updated weekly)

July 13, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Establishment Labs has public SEC filings, moderate analyst coverage from a few firms, and improving market visibility after its Russell 2000 inclusion. Some competitors and market sizing data require reasonable estimates.
bias Check: The main AI bias risk is extrapolating growth trajectory from recent strong revenue trends without fully weighting the binary risks of regulatory setbacks, competitive entry, or a slowdown in elective procedure demand. The stock has more than doubled in the last year, creating a recency bias risk.
ai Confidence: Medium data confidence
investment Certainty: Low-medium. Establishment Labs has a clear growth story and improving financials, but the current valuation assumes a significant ramp in profitability that has not yet materialized. The investment outcome depends on execution, US market adoption, competitive dynamics, and the price paid.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Establishment Labs sells Motiva-brand silicone breast implants and tissue expanders into global aesthetic and reconstructive markets. Revenue is recurring via surgeon loyalty and replacement cycles, but the product is elective and discretionary.	Medium
Moat	The moat comes from surgeon training, brand reputation, proprietary surface technology, regulatory clearances, and distribution relationships. These are real but not insurmountable for well-funded competitors.	Medium-low
Management	Management has grown revenue consistently and expanded geographic reach. The founder sold shares near earnings in June 2026. The hard question is whether the team can deliver the operating leverage needed for sustained GAAP profitability.	Medium
Financial trend	TTM revenue was about $229.58 million, up from prior years. Q1 2026 revenue was $59.88 million. The company is not yet GAAP profitable, with a TTM net loss of $43.74 million and negative free cash flow of $27.83 million.	Medium
Valuation	The stock traded near 11.6x TTM revenue and 43x TTM revenue with a negative PE, so the valuation reflects future profitability expectations rather than current earnings.	Low
Technical trend	ESTA traded near its 52-week high around $90.50, showing strong momentum after a multi-month rally from sub-$40 levels in late 2025.	Medium-high
Risk level	Key risks are elective procedure sensitivity to consumer spending, regulatory changes, competitive entry from larger medical device firms, US market adoption pace, negative earnings, high leverage, and insider selling.	Medium
AI confidence	Medium confidence for revenue trajectory, product positioning, and market data. Lower confidence for future profitability timing and sustainable valuation support.	Medium data confidence
Investment certainty	Low-medium certainty. ESTA has a solid growth story, but the stock price already reflects optimistic assumptions about margin expansion and sustained growth.	Low-medium

ESTA AI stock forecast

ESTA AI Stock Forecast Scenarios

The ESTA AI stock forecast uses scenario ranges around the $89.25 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained Motiva adoption, US market share gains, margin expansion, and eventual GAAP profitability. The base case assumes revenue grows but profitability takes longer than expected. The bearish case assumes growth slows or competitive pressure compresses margins.

Bullish case

$125 to $155

More likely if Establishment Labs sustains 15-20% revenue growth, achieves GAAP profitability within 12 months, gains meaningful US market share, and investors assign a premium multiple on the improved margin profile.

Base case

$70 to $95

More likely if revenue grows at a mid-to-high single digit pace, profitability milestones slip, and the stock trades in line with high-growth medtech peers at roughly 8-10x forward revenue.

Bearish case

$40 to $55

More likely if consumer spending on elective procedures weakens, a major competitor enters the breast implant market with disruptive pricing, US regulatory challenges emerge, or cash burn forces dilutive financing.

ESTA AI technical analysis

ESTA AI Technical Analysis

ESTA AI technical analysis starts from the $89.25 close used for this July 13 static page. Public technical sources showed the stock near its 52-week high of $90.50, well above its 50-day and 200-day moving averages, with RSI in overbought territory. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.

Level	Value	Why it matters
Current price	$89.25	Latest verified close used for this page as of the July 13, 2026 data cutoff.
Near support	$78 to $82	Support planning zone around the 20-day and 50-day moving-average area reported by public technical sources.
Secondary support	$58 to $62	The 200-day moving average area near $60. A sustained break would weaken the long-term technical setup.
Near resistance	$90 to $91	The 52-week high zone. A clean breakout above $91 with volume could open room toward $100.
50-day moving average	About $78 to $80	Public technical sources showed ESTA well above its 50-day moving average around the cutoff.
200-day moving average	About $58 to $62	Public technical sources showed ESTA above its 200-day moving average, supporting the long-term uptrend.
Momentum	RSI elevated, overbought territory	After the rally from $33 to $90, short-term oscillators signaled extended conditions, warranting caution on chasing.
Volume	About 440,000 shares	Volume was below the 601,000 average, suggesting the rally may need volume confirmation for sustained momentum.
Volatility	Beta of 1.07, moderate volatility	Position sizing should account for normal daily swings in a mid-cap medical device stock.
Invalidation	Close below $78, then $60	A close below the 50-day area weakens the near-term setup. A break below the 200-day area would challenge the long trend.

ESTA AI trading strategy

ESTA AI Trading Strategy Framework

The ESTA AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.

Trend-following setup

Look for ESTA to hold above the $78 support zone and break the $90 to $91 resistance area with above-average volume before treating momentum as confirmed.

A failed breakout or daily close below the 50-day area should reduce confidence in the setup.

Mean-reversion setup

If ESTA pulls back toward $78 to $82 without a thesis break, compare price stabilization with upcoming earnings, US market adoption data, and margin progression signals.

Do not average down solely because the stock had a strong run. Define maximum loss and review valuation first.

Fundamental monitor

Track Q2 2026 results, revenue growth rate, gross margin trend, operating expense leverage, cash burn, US market revenue share, and any competitive landscape changes.

Lower the rating if revenue growth decelerates while the stock still trades at a premium revenue multiple.

Investment research summary

Four-master Research Compression

Business essence

Establishment Labs designs, manufactures, and sells Motiva-brand silicone breast implants and tissue expanders for aesthetic and reconstructive surgery through a global network of distributors and direct sales.

Moat

The moat is built on surgeon training programs, brand equity among plastic surgeons, proprietary surface technology, regulatory approvals across markets, and established distribution relationships.

Munger risk inversion

The thesis can fail if consumer spending on elective aesthetics weakens during an economic downturn, a larger competitor enters with price pressure, US market adoption disappoints, regulatory changes impact the product, or the company cannot reach GAAP profitability before needing dilutive capital.

Management

Leadership has delivered consistent revenue growth and geographic expansion. The June 2026 insider sale by the founder of $7.9 million on earnings day is a flag worth monitoring for conviction signals.

Industry trend

Establishment Labs operates at the intersection of medical aesthetics, a growing industry driven by aging demographics, rising disposable income, and increasing social acceptance of cosmetic procedures. The trend is favorable long-term but cyclical.

Valuation and margin of safety

At roughly 11.6x TTM revenue and a negative PE, the price embeds optimistic assumptions about future profitability. A buyer needs confidence in sustained growth and margin expansion to justify the current multiple.

Source-backed data

ESTA Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
ESTA price	$89.25 close on July 2, 2026	Yahoo Finance quote snapshot	July 13, 2026
Market capitalization	$2.63 billion as of recent close	Yahoo Finance and SEC filings	July 13, 2026
TTM revenue	$229.58 million	Yahoo Finance and SEC filings	July 13, 2026
TTM net income	-$43.74 million	Yahoo Finance and SEC filings	July 13, 2026
Q1 FY2026 revenue	$59.88 million	Establishment Labs Q1 2026 earnings release	July 13, 2026
Cash and equivalents	$68.1 million	Yahoo Finance balance sheet data	July 13, 2026
Enterprise value	$2.82 billion	Yahoo Finance statistics	July 13, 2026
Price to sales ratio (TTM)	11.58x	Yahoo Finance key statistics	July 13, 2026
Analyst consensus	Buy, average price target $91.22	Yahoo Finance and BTIG rating of Buy with $90 PT	July 13, 2026
52-week range	$33.35 to $90.50	Yahoo Finance statistics	July 13, 2026
Levered free cash flow (TTM)	-$27.83 million	Yahoo Finance cash flow data	July 13, 2026

Frequently Asked Questions

Read the GKOS AI stock analysis View the SIBN AI stock forecast Explore AI Stock Picker Generate an AI trading strategy

This ESTA AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong.